HSD17B1 Antibodies

Estradiol 17-beta-dehydrogenase 1 (HSD17B1)

Favors the reduction of estrogens and androgens. Also has 20-alpha-HSD activity.

Uses preferentially NADH. .

Gene Information

Human
Gene Name:	HSD17B1
Uniprot:	P14061
Entrez:	3292

Family

Belongs to:
short-chain dehydrogenases/reductases (SDR) family

Alternative Names

17 betaHSD1; 17 beta-HSD1; 17-beta-HSD 1; 17-beta-hydroxysteroid dehydrogenase type 1; 20 alpha-hydroxysteroid dehydrogenase; 20-alpha-HSD; E17KSR; E2DH; EC 1.1.1.62; EDH17B1; EDH17B2; EDH17B2EDHB17; EDHB17; estradiol 17-beta-dehydrogenase 1; estradiol 17-beta-dehydrogenase-1; HSD17; HSD17B1; hydroxysteroid (17-beta) dehydrogenase 1 isoform; hydroxysteroid (17-beta) dehydrogenase 1; MGC138140; Placental 17-beta-hydroxysteroid dehydrogenase; SDR28C1; short chain dehydrogenase/reductase family 28CE, member 1

Molecular Weight

Mass (kDA):
34.95 kDA

Genomic Context

Human
Location:	17q21.2
Sequence:	17; NC_000017.11 (42552923..42555214)

Subcellular Localizations

Cytoplasm.

Diseases

• Malignant Neoplasms
• Malignant Neoplasm Of Breast
• Mammary Neoplasms
• Neoplasms
• Endometriosis, Site Unspecified
• Endometrial Polyp
• Malignant Neoplasm Of Prostate
• Steroid Sulfatase Deficiency Disease
• Prostatic Neoplasms
• Endometrial Neoplasms
• Endometrial Carcinoma
• Colorectal Cancer
• Colorectal Neoplasms

• Choriocarcinoma
• Carcinoma
• Carcinogenesis
• Infertility
• Neoplasms, Germ Cell And Embryonal
• Neoplasms, Hormone-dependent
• Testicular Germ Cell Tumor

Pathways

• Secretion
• Cell Proliferation
• Transport
• Pathogenesis
• Translation
• Dna Methylation
• Methylation
• Decidualization
• Prolactin Secretion
• Cell Adhesion
• Progesterone Secretion
• Gene Silencing

• Dna Hypermethylation
• Fertilization
• Brain Development
• Immune Response
• Spermatogenesis
• Cell Division
• Menstruation

PTMs

• Cleavage
• Methylation
• Demethylation

• Phosphorylation
• Reduction
• Hydroxylation

• Glycosylation

Research Areas

• Breast Cancer
• Cancer

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/HSD17B1

Best Uses Of The HSD17B1 Marker

The HSD17B1 biomarker is highly versatile and can be used for diagnostic, predictive, and indicative purposes. This marker can be used to diagnose advanced liver fibrosis and other conditions. It is not yet available for all diagnostic tests, despite its versatility. Below are the methods of the invention. We will go into detail about each use.

Diagnostic

HSD17B1 gene expression was studied in primary colonic carcinoma tissues and colorectal tumor cell lines. 52 patients were examined. Histopathologically normal colonic muscula were obtained from all. DNA methylation was assessed using bisulfite DNA sequencing, HRM analysis, and ChIP analysis. Estrone was also measured using electrochemiluminescence.

The methylation status of HSD17B1 was evaluated using HRM analysis. The results of the methylation were compared with those obtained using standard DNAPCR. The HRM profile was calculated using software called Precision Melt Analysis(tm) by Bio-Rad Laboratories. Each patient sample was analysed in triplicate. The percentage methylation of the three amplified HSD17B1 fragments was then expressed.

Eight miRNAs, five genes and HSD17B1/HSD17B2 are responsible for regulating the expression of these enzymes. These eight miRNAs have been identified, which provides additional insight into the complex control mechanisms for these enzymes. Future research will reveal their exact roles in breast-cancer. HSD17B1 & HSD17B2 expression levels were correlated with treatment response and stage.

Breast tumors in women who are hormone deficient increase when this gene is expressed. The HSD17B1 gene is associated lower with local recurrence. This gene is essential for the regulation of estrogen-positive breast cancer. The metabolism of estrogen involves the HSD17B1 genes. HSD17B1 promotes expression of genes that inhibit the apoptosis process.

Two colorectal tumor cell lines (HT29 &SW707) were used to test whether 5-dAzaC regulates HSD17B1 protein expression. The total RNA was isolated and reverse-transcribed. RQPCR relative quantification was used as a method to determine the HSD17B1 cDNA levels. The levels are expressed by the multiplicity (or number) of the control samples. All samples were tested in triplicate. The mean and standard deviation of three experiments are presented.

HSD17B1 may also increase the risk of Alzheimer’s in premenopausal patients. Additionally, a higher mRNA level of HSD17B1 has been associated with a lower incidence rate of ER+-related breast cancer in premenopausal woman. HSD17B1 may also affect the blood levels of central estrogen. Further research in this field may help us to understand the genetic factors that lead to dementia and cognitive decline.

Predictive

Preeclamptic pregnancy can be predicted by the presence of HSD17B1 in the placenta. This marker is dysregulated by miR-210 and miR-518c, which are aberrantly expressed in the preeclamptic placenta. A prognostic factor could also be a decrease in HSD17B1 levels in plasma before PE.

Plasma HSD17B1 levels have been measured in pregnant women before they develop late-onset PE. The results showed a negative association with low plasma HSD17B1 levels, and PE. A prospective cohort study also found that HSD17B1 levels predict the onset and severity of late-onset PE. Although the results were not statistically significant they support the idea that HSD17B1 may be a useful marker to predict early-onset PE.

Two large studies were done to investigate this: one using data from the general population and the second using data from postmenopausal women. HSD17B1 genes were not associated with breast cancer in the first study. However, the second study showed that it was. Furthermore, the HSD17B1 polymorphism was not predictive of stage I or II breast cancer, which led to further studies of HSD17B1 genotypes in women.

The study also showed that patients with breast cancer had a high IRDS status, which was a good indicator of local-regional failure. The results of breast cancer showed an increase in predictive value when combined with other prognostic factors such as age and ER status. A recent study also found that TSP IRDS scores improved the predictive ability of IRDS-positive patients following adjuvant treatment.

Other studies using the same gene HSD17B1 reported that the IRDS signature was a strong predictor for breast cancer patients. Resistance to radiation therapy or adjuvant chemotherapy is associated with the expression of IRDS gene signature. These markers can be used to detect patients who are likely or not to respond to the treatment. This research is the earliest to demonstrate the predictive value of HSD17B1 as a marker for cancer.

MiR-218c and miR-518c target HSD17B1's 3'-untranslated regions. These miRNAs reduce HSD17B1 transcription. Moreover, these miRNAs are highly effective in predicting the outcome of a disease. These results highlight the potential of HSD17B1 as a biomarker in cancer. In addition to being an accurate diagnostic tool, HSD17B1 has also shown promise in developing new treatment options.

Indicative

HSD17A1 has been described as an indicator of its use. This gene is highly expressed within the ESCd. It regulates the immune system and apoptosis. Other important functions include regulation of epigenetics as well as apoptosis. These studies suggest that HSD17B1 might help in predicting preeclampsia development in women.